Exclusive low-dose-rate brachytherapy in 279 patients with T2N0 mobile tongue carcinoma

详细信息	查看全文 | 推荐本文 |

• 作者：Cé ; line Bourgier ; Bernard Coche-Dé ; qué ; ant ; Charles Fournier ; Bernard Castelain ; Bernard Pré ; vost ; Jean-Louis Lefebvre and Eric Lartigau
• 刊名：International Journal of Radiation Oncology*Biology*Physics
• 出版年：2005
• 期刊代码：136_03603016
• 类别：med
• 出版时间：2005
• 卷：63
• 期：2
• 页码：434-440
• 文件大小：269 K

摘要

Purpose: To evaluate the therapeutic results obtained with ¹⁹²Ir low-dose-rate interstitial brachytherapy in T2N0 mobile tongue carcinoma. Patients and Methods: Between December 1979 and January 1998, 279 patients with T2N0 mobile tongue carcinoma were treated by exclusive low-dose-rate brachytherapy, with or without neck dissection. ¹⁹²Ir brachytherapy was performed according to the “Paris system” with a median total dose of 60 Gy (median dose rate, 0.5 Gy/h). Results: Overall survival was 74.3%and 46.6%at 2 and 5 years. Local control was 79.1%at 2 years and regional control, respectively, 75.9%and 69.5%at 2 and 5 years (Kaplan–Meier method). Systematic dissection revealed 44.6%occult node metastases, and histologic lymph node involvement was identified as the main significant factor for survival. Complication rate was 16.5%(Grade 3, 2.9%). Half of the patients presented previous and/or successive malignant tumor (ear-nose-throat, esophagus, or bronchus). Conclusion: Exclusive low-dose-rate brachytherapy is an effective treatment for T2 tongue carcinoma. Regional control and survival are excellent in patients undergoing systematic neck dissection, which is mandatory in our experience because of a high rate of occult lymph node metastases.